MONOCLONAL ANTIBODY FOR CANCER TREATMENT (Q3133637): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Removed claims) |
||||||
Property / budget | |||||||
| |||||||
Property / budget: 5,624,739.0 Euro / rank | |||||||
Property / co-financing rate | |||||||
| |||||||
Property / co-financing rate: 50.0 percent / rank | |||||||
Property / EU contribution | |||||||
| |||||||
Property / EU contribution: 2,812,369.5 Euro / rank | |||||||
Revision as of 15:06, 20 October 2021
Project Q3133637 in Spain
Language | Label | Description | Also known as |
---|---|---|---|
English | MONOCLONAL ANTIBODY FOR CANCER TREATMENT |
Project Q3133637 in Spain |
Statements
16 February 2015
0 references
14 December 2015
0 references
ALTHIA HEALTH S.L.
0 references
28079
0 references
VALIDACIÓN DE UN ANTICUERPO MONOCLONAL PARA LA DETECCIÓN Y TRATAMIENTO DE CÉLULAS MADRE DEL CÁNCER EN TUMORES DE CEREBRO (Spanish)
0 references
VALIDATION OF A MONOCLONAL ANTIBODY FOR THE DETECTION AND TREATMENT OF CANCER MOTHER CELLS IN BRAIN TUMORS (English)
0 references
Madrid
0 references
Identifiers
DGEPF/01/21/002-17/18
0 references